Bill Farley

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.